Raymond James & Associates Mereo Biopharma Group PLC Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding MREO
# of Institutions
87Shares Held
107MCall Options Held
209KPut Options Held
479K-
Rubric Capital Management LP New York, NY15.3MShares$44.4 Million1.75% of portfolio
-
Janus Henderson Group PLC London, X012.3MShares$35.8 Million0.03% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA9.72MShares$28.2 Million0.07% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD9.53MShares$27.6 Million1.33% of portfolio
-
Mangrove Partners New York, NY8.73MShares$25.3 Million4.66% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $362M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...